Agenus appoints Jennifer Buell to Board of Directors, stresses BOT/BAL BLA filing

AGENUS INC

Dr. Jennifer Buell appointed to Agenus Board effective June 11, 2024.
Buell remains President/CEO of MiNK Therapeutics and Chairman of Agenus Executive Council.
Priority is to guide BOT/BAL program toward Biologics License Application submission this year.
Brings 27+ years biopharma experience; previously served as President & COO of Agenus.
No committee assignments; previously granted options for 37,500 shares (2023 and 2024).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jennifer Buell

Director

AGEN · AGENUS INC

Effective: 2024-06-11
Filed: June 17, 2024, 7:59 PM ET

Dr. Jennifer Buell was appointed to the Board of Directors of Agenus Inc. (Agenus) on June 11, 2024, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jennifer Buell was appointed as Director at AGENUS INC.

Action: appointed
Role: Director

Exact text from the filing

Dr. Jennifer Buell was appointed to the Board of Directors of Agenus Inc. (Agenus) on June 11, 2024, effective immediately.

View on SEC.gov

AGENUS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-074231

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.